Peter Mcconnell, MD | |
156 Valley View Dr, Belle Vernon, PA 15012-9614 | |
(724) 872-2552 | |
Not Available |
Full Name | Peter Mcconnell |
---|---|
Gender | Male |
Speciality | Obstetrics & Gynecology |
Location | 156 Valley View Dr, Belle Vernon, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689005340 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | MD046395L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Peter Mcconnell, MD 156 Valley View Dr, Belle Vernon, PA 15012-9614 Ph: (724) 872-2552 | Peter Mcconnell, MD 156 Valley View Dr, Belle Vernon, PA 15012-9614 Ph: (724) 872-2552 |
News Archive
The Program in Heart Failure and Transplantation at the University of Rochester Medical Center has reached a milestone, performing its 100th cardiac transplant surgery.
A review carried out by the University of Hull has shed new light on the relationship between acne and diet. Published in Dermatological Nursing, the comprehensive review assesses the latest evidence and findings about the effects of food and nutrition on acne and suggest that high glycemic index foods such as milk could exacerbate the skin condition.
US Oncology, Inc., the nation's leading integrated oncology company, announced today that three investigators affiliated with US Oncology Research participated in studies that will be presented orally at the 52nd American Society of Hematology Annual Meeting and Exposition at the Orange County Convention Center in Orlando, Fla. Dec. 4-7. Five other investigators in the US Oncology Research Network participated in a study that will be displayed as a poster during the conference.
Depomed, Inc. today announced that it has received a $10 million milestone payment from Abbott Products, Inc., its licensee of DM-1796, for the U.S. Food and Drug Administration's acceptance for filing of the New Drug Application (NDA) for DM-1796 for the management of postherpetic neuralgia (PHN), or pain after shingles.
› Verified 7 days ago